Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer
Abstract Chimeric antigen receptor (CAR) T‐cell therapy is a new successful treatment for refractory B‐cell leukemia. Successful therapeutic outcome depends on long‐term expression of CAR transgene in T cells, which is achieved by delivering transgene using integrating gamma retrovirus (RV) or lenti...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2016-05-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.201505869 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849761559189913600 |
|---|---|
| author | Chuan Jin Grammatiki Fotaki Mohanraj Ramachandran Berith Nilsson Magnus Essand Di Yu |
| author_facet | Chuan Jin Grammatiki Fotaki Mohanraj Ramachandran Berith Nilsson Magnus Essand Di Yu |
| author_sort | Chuan Jin |
| collection | DOAJ |
| description | Abstract Chimeric antigen receptor (CAR) T‐cell therapy is a new successful treatment for refractory B‐cell leukemia. Successful therapeutic outcome depends on long‐term expression of CAR transgene in T cells, which is achieved by delivering transgene using integrating gamma retrovirus (RV) or lentivirus (LV). However, uncontrolled RV/LV integration in host cell genomes has the potential risk of causing insertional mutagenesis. Herein, we describe a novel episomal long‐term cell engineering method using non‐integrating lentiviral (NILV) vector containing a scaffold/matrix attachment region (S/MAR) element, for either expression of transgenes or silencing of target genes. The insertional events of this vector into the genome of host cells are below detection level. CD19 CAR T cells engineered with a NILV‐S/MAR vector have similar levels of CAR expression as T cells engineered with an integrating LV vector, even after numerous rounds of cell division. NILV‐S/MAR‐engineered CD19 CAR T cells exhibited similar cytotoxic capacity upon CD19+ target cell recognition as LV‐engineered T cells and are as effective in controlling tumor growth in vivo. We propose that NILV‐S/MAR vectors are superior to current options as they enable long‐term transgene expression without the risk of insertional mutagenesis and genotoxicity. |
| format | Article |
| id | doaj-art-baffc314e99e407f8134e568e1e6c5ca |
| institution | DOAJ |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2016-05-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-baffc314e99e407f8134e568e1e6c5ca2025-08-20T03:06:00ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842016-05-018770271110.15252/emmm.201505869Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transferChuan Jin0Grammatiki Fotaki1Mohanraj Ramachandran2Berith Nilsson3Magnus Essand4Di Yu5Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala UniversityAbstract Chimeric antigen receptor (CAR) T‐cell therapy is a new successful treatment for refractory B‐cell leukemia. Successful therapeutic outcome depends on long‐term expression of CAR transgene in T cells, which is achieved by delivering transgene using integrating gamma retrovirus (RV) or lentivirus (LV). However, uncontrolled RV/LV integration in host cell genomes has the potential risk of causing insertional mutagenesis. Herein, we describe a novel episomal long‐term cell engineering method using non‐integrating lentiviral (NILV) vector containing a scaffold/matrix attachment region (S/MAR) element, for either expression of transgenes or silencing of target genes. The insertional events of this vector into the genome of host cells are below detection level. CD19 CAR T cells engineered with a NILV‐S/MAR vector have similar levels of CAR expression as T cells engineered with an integrating LV vector, even after numerous rounds of cell division. NILV‐S/MAR‐engineered CD19 CAR T cells exhibited similar cytotoxic capacity upon CD19+ target cell recognition as LV‐engineered T cells and are as effective in controlling tumor growth in vivo. We propose that NILV‐S/MAR vectors are superior to current options as they enable long‐term transgene expression without the risk of insertional mutagenesis and genotoxicity.https://doi.org/10.15252/emmm.201505869CAR T cellsepisomal cell engineeringnon‐integrating lentivirus (NILV)scaffold/matrix attachment region (S/MAR) elementself‐replicating DNA |
| spellingShingle | Chuan Jin Grammatiki Fotaki Mohanraj Ramachandran Berith Nilsson Magnus Essand Di Yu Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer EMBO Molecular Medicine CAR T cells episomal cell engineering non‐integrating lentivirus (NILV) scaffold/matrix attachment region (S/MAR) element self‐replicating DNA |
| title | Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer |
| title_full | Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer |
| title_fullStr | Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer |
| title_full_unstemmed | Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer |
| title_short | Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer |
| title_sort | safe engineering of car t cells for adoptive cell therapy of cancer using long term episomal gene transfer |
| topic | CAR T cells episomal cell engineering non‐integrating lentivirus (NILV) scaffold/matrix attachment region (S/MAR) element self‐replicating DNA |
| url | https://doi.org/10.15252/emmm.201505869 |
| work_keys_str_mv | AT chuanjin safeengineeringofcartcellsforadoptivecelltherapyofcancerusinglongtermepisomalgenetransfer AT grammatikifotaki safeengineeringofcartcellsforadoptivecelltherapyofcancerusinglongtermepisomalgenetransfer AT mohanrajramachandran safeengineeringofcartcellsforadoptivecelltherapyofcancerusinglongtermepisomalgenetransfer AT berithnilsson safeengineeringofcartcellsforadoptivecelltherapyofcancerusinglongtermepisomalgenetransfer AT magnusessand safeengineeringofcartcellsforadoptivecelltherapyofcancerusinglongtermepisomalgenetransfer AT diyu safeengineeringofcartcellsforadoptivecelltherapyofcancerusinglongtermepisomalgenetransfer |